{"id":4042,"date":"2021-01-13T15:10:00","date_gmt":"2021-01-13T15:10:00","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/"},"modified":"2021-01-13T15:10:00","modified_gmt":"2021-01-13T15:10:00","slug":"nanexa-valjer-lenalidomid-for-produktprojektet-nex-20","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/","title":{"rendered":"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB meddelar idag att bolaget har valt att utveckla en l\u00e5ngtidsverkande formulering av lenalidomid f\u00f6r behandling av multipelt myelom. NEX-20 blir bolagets andra egna produktprojekt.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>\u201dEfter en noggrann utv\u00e4rdering av kliniska behov, marknadspotential och tekniska m\u00f6jligheter, har vi nu valt lenalidomid f\u00f6r NEX-20. Lenalidomid \u00e4r en utm\u00e4rkt substans eftersom den \u00e4r och kommer att f\u00f6rbli ett viktigt l\u00e4kemedel f\u00f6r behandling av multipelt myelom under m\u00e5nga \u00e5r fram\u00f6ver. Vi ser fram emot att p\u00e5b\u00f6rja den prekliniska utvecklingen av lenalidomid inom kort.\u201d, s\u00e4ger David Westberg, vd f\u00f6r Nanexa.<\/p>\n<p>Globalt st\u00e5r multipelt myelom f\u00f6r cirka en procent av alla cancerdiagnoser och cirka tio procent av alla diagnoser inom hematologisk cancer (blodcancer). Detta motsvarar cirka 60 000 nya fall av multipelt myelom varje \u00e5r i US, UK och EU4. F\u00f6rs\u00e4ljningen av l\u00e4kemedel mot multipelt myelom ber\u00e4knas uppg\u00e5 till 22 miljarder dollar \u00e5r 2027.[1]<\/p>\n<p>Patienter som idag behandlas med Bristol Myers Squibb\/Celgenes Revlimid (lenalidomid) f\u00e5r en dos dagligen i tre till fyra veckor under en 28-dagarscykel. Med Nanexas unika PharmaShell\u00ae-teknologi kan dessa doseringar komma att ers\u00e4ttas med endast en injektion per 28 dagar.<\/p>\n<p>\u201dEfterlevnaden av behandling med lenalidomid \u00e4r idag f\u00f6rv\u00e5nansv\u00e4rt l\u00e5g. I en studie[2] av patienter nyligen diagnostiserade med multipelt myelom, ans\u00e5gs 38 procent inte f\u00f6lja ordinerad behandling, vilket p\u00e5 l\u00e5ng sikt kan leda till en f\u00f6rs\u00e4mrad prognos. Det \u00e4r den patientgruppen som kommer att vara v\u00e5r huvudsakliga m\u00e5lgrupp f\u00f6r NEX-20 projektet.\u201d, s\u00e4ger David Westberg.<\/p>\n<p>\u201dEn l\u00e5ngverkande dep\u00e5formulering av lenalidomid kan vara ett viktigt tillskott till dagens behandlingsalternativ, s\u00e4rskilt f\u00f6r patienter som f\u00e5r l\u00f6pande behandling med stabila doser under relativt l\u00e5nga tidsperioder. Det kan \u00f6ka efterlevnaden och s\u00e5 sm\u00e5ningom bidra till en f\u00f6rb\u00e4ttrad behandlingseffekt f\u00f6r specifika patientgrupper. Detta projekt, tillsammans med NEX-18, g\u00f6r det m\u00f6jligt f\u00f6r Nanexa att skapa en v\u00e4rdefull portf\u00f6lj inom hematologiska cancerformer \u201d, s\u00e4ger professor Dr. Axel Glasmacher, oberoende konsult.<\/p>\n<p>Patentet f\u00f6r Revlimid g\u00e5r ut 2022 vilket kommer leda till ett minskat totalt f\u00f6rs\u00e4ljningsv\u00e4rde av lenalidomid, men f\u00f6rs\u00e4ljningsvolymen kommer att kvarst\u00e5. Unders\u00f6kningsf\u00f6retaget Global Data uppskattar att marknaden f\u00f6r lenalidomid \u00e4ven efter patentutg\u00e5ng kommer vara betydande med en f\u00f6rs\u00e4ljning p\u00e5 1,3 miljarder dollar, 2027 (US, UK och EU4) och en patientgrupp p\u00e5 ca 150\u00a0000 patienter.[1]<\/p>\n<p>Nanexas f\u00f6rsta egna produktprojekt NEX-18 med substansen 5-azacytidin \u00e4r ocks\u00e5 den inriktad p\u00e5 en hematologisk cancerform; myelodysplastiskt syndrom\u00a0(MDS). Nanexa har nyligen f\u00e5tt godk\u00e4nnande fr\u00e5n L\u00e4kemedelsverket f\u00f6r att starta en fas I-studie f\u00f6r NEX-18, som ber\u00e4knas p\u00e5b\u00f6rjas under f\u00f6rsta kvartalet 2021.<\/p>\n<p>\u201dDen kunskap vi byggt upp inom bolaget inom formulering med PharmaShell\u00ae och hematologisk cancer \u00e4r naturligtvis av stort v\u00e4rde n\u00e4r vi nu tar v\u00e5rt andra projekt mot klinisk utveckling. Den n\u00e4rmaste tiden kommer att \u00e4gnas \u00e5t formulerings- och preklinisk utveckling. Vi hoppas kunna ta projektet in i klinisk utveckling under 2022.\u201d, avslutar David Westberg.<\/p>\n<p>[1] Global Data Multiple Myelom forecast, mars 2019 f\u00f6r USA, Japan, EU4, Storbritannien och Kina<br \/>[2] H Mian et-al Clinical Lymphoma, Myeloma and Leukemia, september, 2019<br \/>\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna projekt och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2021-01-13 16:10 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-pdf\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/0a13b1b9-5ba4-4302-8b33-5f07ba2e3ec9\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20.pdf\" rel=\"nofollow noopener\">Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB meddelar idag att bolaget har valt att utveckla en l\u00e5ngtidsverkande formulering av lenalidomid f\u00f6r behandling av multipelt myelom. NEX-20 blir bolagets andra egna produktprojekt.<\/p>\n","protected":false},"template":"","class_list":["post-4042","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att bolaget har valt att utveckla en l\u00e5ngtidsverkande formulering av lenalidomid f\u00f6r behandling av multipelt myelom. NEX-20 blir bolagets andra egna produktprojekt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\\\/\",\"name\":\"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-01-13T15:10:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20 - Nanexa AB","og_description":"Nanexa AB meddelar idag att bolaget har valt att utveckla en l\u00e5ngtidsverkande formulering av lenalidomid f\u00f6r behandling av multipelt myelom. NEX-20 blir bolagets andra egna produktprojekt.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/","name":"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-01-13T15:10:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-lenalidomid-for-produktprojektet-nex-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa v\u00e4ljer lenalidomid f\u00f6r produktprojektet NEX-20"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/4042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=4042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}